极低出生体重儿早期产后大剂量脂溶性肠内维生素A补充对中重度支气管肺发育不良或死亡的影响(NeoVitaA):多中心、随机、平行组、双盲、安慰剂对照、研究者发起的3期试验
该多中心、随机、双盲、安慰剂对照3期试验在奥地利和德国29个新生儿重症监护病房纳入915例极低出生体重儿(出生体重>400 g且<1000 g,胎龄≤32+0周,生后72小时内需机械通气、无创呼吸支持或补氧),随机接受肠内大剂量维生素A(5000 IU/kg/天)或安慰剂(花生油)治疗28天,所有患儿均接受基础维生素A补充(1000 IU/kg/天)。主要复合终点为36周矫正胎龄时中重度支气管肺发育不良或死亡,高剂量组171/449例(38%)vs 对照组178/466例(38%),校正OR 0.99(95%CI 0.73-1.55)。至少发生一次不良事件的比例两组相似(256/449例[57%] vs 281/466例[60%])。作者结论:早期产后大剂量脂溶性肠内维生素A补充安全,但未改变中重度支气管肺发育不良或死亡发生率,也未显著提高血清视黄醇浓度。
要点
- 极低出生体重儿早期产后补充大剂量肠内维生素A(5000 IU/kg/天×28天)未降低36周矫正胎龄时中重度支气管肺发育不良或死亡:高剂量组38% vs 对照组38%,校正OR 0.99(95%CI 0.73-1.55)。
- 至少一次不良事件两组相似:高剂量组256/449例(57%)vs 对照组281/466例(60%),提示该方案安全。
- 基线、干预结束时及36周矫正胎龄时血清视黄醇浓度两组相似,大剂量补充未显著提高血清视黄醇浓度。
- 所有患儿均接受基础维生素A补充1000 IU/kg/天,大剂量组在此基础上额外补充5000 IU/kg/天。
- 研究纳入出生体重>400 g且<1000 g、胎龄≤32+0周、生后72小时内需机械通气、无创呼吸支持或补氧的极低出生体重儿。
适用人群与场景
- 出生体重>400 g且<1000 g的极低出生体重儿,胎龄≤32+0周,入住新生儿重症监护病房后生后72小时内需机械通气、无创呼吸支持或补充氧气。
处置流程与药物剂量
- 所有参与者接受基础维生素A补充1000 IU/kg/天;高剂量组额外肠内补充维生素A 5000 IU/kg/天,疗程28天;对照组给予安慰剂(花生油)。
研究设计与关键结果
- 多中心、随机、平行组、双盲、安慰剂对照、研究者发起的3期试验,在奥地利和德国29个新生儿重症监护病房开展;2015年3月2日至2022年2月27日筛查3066例,纳入915例,随机分为高剂量维生素A组(n=449)和对照组(n=466)。
- 平均胎龄26.5周(SD 2.0),平均出生体重765 g(162)。
- 主要复合终点(36周矫正胎龄时中重度支气管肺发育不良或死亡)在高剂量维生素A组171/449例(38%)vs 对照组178/466例(38%),校正OR 0.99(95%CI 0.73-1.55)。
- 至少发生一次不良事件:高剂量维生素A组256/449例(57%)vs 对照组281/466例(60%)。
- 基线、干预结束时及36周矫正胎龄时血清视黄醇浓度两组相似。
证据类型、等级与局限
- 证据类型:多中心、随机、平行组、双盲、安慰剂对照、研究者发起的3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:极低出生体重儿早期产后大剂量脂溶性肠内维生素A补充安全,但未改变中重度支气管肺发育不良或死亡发生率,也未显著提高血清视黄醇浓度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vitamin A plays a key role in lung development, but there is no consensus regarding the optimal vitamin A dose and administration route in extremely low birthweight (ELBW) infants. We aimed to assess whether early postnatal additional high-dose fat-soluble enteral vitamin A supplementation versus placebo would lower the rate of moderate or severe bronchopulmonary dysplasia or death in ELBW infants receiving recommended basic enteral vitamin A supplementation.
METHODS: This prospective, multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial conducted at 29 neonatal intensive care units in Austria and Germany assessed early high-dose enteral vitamin A supplementation (5000 international units [IU]/kg per day) or placebo (peanut oil) for 28 days in ELBW infants. Eligible infants had a birthweight of more than 400 g and less than 1000 g; gestational age at birth of 32+0 weeks postmenstrual age or younger; and the need for mechanical ventilation, non-invasive respiratory support, or supplemental oxygen within the first 72 h of postnatal age after admission to the neonatal intensive care unit. Participants were randomly assigned by block randomisation with variable block sizes (two and four). All participants received basic vitamin A supplementation (1000 IU/kg per day). The composite primary endpoint was moderate or severe bronchopulmonary dysplasia or death at 36 weeks postmenstrual age, analysed in the intention-to-treat population. This trial was registered with EudraCT, 2013-001998-24.
FINDINGS: Between March 2, 2015, and Feb 27, 2022, 3066 infants were screened for eligibility at the participating centres. 915 infants were included and randomly assigned to the high-dose vitamin A group (n=449) or the control group (n=466). Mean gestational age was 26·5 weeks (SD 2·0) and mean birthweight was 765 g (162). Moderate or severe bronchopulmonary dysplasia or death occurred in 171 (38%) of 449 infants in the high-dose vitamin A group versus 178 (38%) of 466 infants in the control group (adjusted odds ratio 0·99, 95% CI 0·73-1·55). The number of participants with at least one adverse event was similar between groups (256 [57%] of 449 in the high-dose vitamin A group and 281 [60%] of 466 in the control group). Serum retinol concentrations at baseline, at the end of intervention, and at 36 weeks postmenstrual age were similar in the two groups.
INTERPRETATION: Early postnatal high-dose fat-soluble enteral vitamin A supplementation in ELBW infants was safe, but did not change the rate of moderate or severe bronchopulmonary dysplasia or death and did not substantially increase serum retinol concentrations.
FUNDING: Deutsche Forschungsgemeinschaft and European Clinical Research Infrastructures Network (ECRIN).
参考来源
- Meyer S, Bay J, Franz AR, et al. Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial. Lancet Respir Med. 2024. PMID: 38643780. doi:10.1016/S2213-2600(24)00073-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。